Company: SMNR
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001213900-25-044889
Chunk: 2

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
The accompanying notes are an integral part of these unaudited condensed financial statements.

2

DENALI CAPITAL ACQUISITION CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN SHAREHOLDERS’ DEFICIT

(Unaudited)

    For the Three Months Ended March 31, 2025 

    Class A Ordinary Shares  
    Class B Ordinary Shares  
    Accumulated  
    Shareholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Deficit  
    Deficit 
  
    Balance as of December 31, 2024 (Audited) 
     510,000  
     51  
     2,062,500  
     206  
    $(10,417,973) 
     (10,417,716)
  
    Net income 
     -  
     -  
     -  
     -  
     (194,603) 
     (194,603)
  
    Subsequent measurement of ordinary shares subject to possible redemption (interest earned on trust account and extension deposit) 
     -  
     -  
     -  
     -  
     (124,162) 
     (124,162)
  
    Balance as of March 31, 2025 (Unaudited) 
     510,000  
     51  
     2,062,500  
     206  
    $(10,736,738) 
     (10,736,481)

    For the Three Months Ended March 31, 2024 

    Class A 
Ordinary Shares  
    Class B 
Ordinary Shares  
    Accumulated  
    Shareholders’
 Equity 

    Shares  
    Amount  
    Shares  
    Amount  
    Deficit  
     Deficit 
  
    Balance as of December 31, 2023 (Audited) 
     510,000  
    $51  
    $2,062,500  
    $206  
    $(8,282,297) 
    $     (8,282,040)
  
    Net income 
     -  
     -  
     -  
     -  
     264,330